![Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer – A randomized controlled trial - The Breast Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer – A randomized controlled trial - The Breast](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/525b57a4-6500-40f8-9d79-7c96e858239c/gr1_lrg.jpg)
Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer – A randomized controlled trial - The Breast
![Exploring the use of Mobile applications by cancer patients undergoing chemotherapy: A scoping review - ScienceDirect Exploring the use of Mobile applications by cancer patients undergoing chemotherapy: A scoping review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1386505620307437-gr1.jpg)
Exploring the use of Mobile applications by cancer patients undergoing chemotherapy: A scoping review - ScienceDirect
![PDF) Probiotic supplementation attenuates the aggressiveness of chemically induced colorectal tumor in rats PDF) Probiotic supplementation attenuates the aggressiveness of chemically induced colorectal tumor in rats](https://i1.rgstatic.net/publication/336453814_Probiotic_supplementation_attenuates_the_aggressiveness_of_chemically_induced_colorectal_tumor_in_rats/links/5da8d6ef4585155e27f633d0/largepreview.png)
PDF) Probiotic supplementation attenuates the aggressiveness of chemically induced colorectal tumor in rats
![PDF) Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine PDF) Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine](https://i1.rgstatic.net/publication/10659951_Lactobacillus_acidophilus_Bifidobacterium_lactis_and_Lactobacillus_F19_prevent_antibiotic-associated_ecological_disturbances_of_Bacteroides_fragilis_in_the_intestine/links/0deec52d3f46e4aed7000000/largepreview.png)
PDF) Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine
![PDF) Study of pattern of adverse drug reaction due to cancer chemotherapy and their management in hospitalized patient in BP Koirala Memorial Cancer Hospital PDF) Study of pattern of adverse drug reaction due to cancer chemotherapy and their management in hospitalized patient in BP Koirala Memorial Cancer Hospital](https://i1.rgstatic.net/publication/276328503_Study_of_pattern_of_adverse_drug_reaction_due_to_cancer_chemotherapy_and_their_management_in_hospitalized_patient_in_BP_Koirala_Memorial_Cancer_Hospital/links/5672989708aeb8b21c70cf39/largepreview.png)
PDF) Study of pattern of adverse drug reaction due to cancer chemotherapy and their management in hospitalized patient in BP Koirala Memorial Cancer Hospital
![Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review – topic of research paper in Veterinary science. Download scholarly article PDF and read for Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review – topic of research paper in Veterinary science. Download scholarly article PDF and read for](https://cyberleninka.org/viewer_images/1032011/f/1.png)
Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review – topic of research paper in Veterinary science. Download scholarly article PDF and read for
![Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/66fb1f4d-1219-4c00-b446-cb218ddde96e/gr1.gif)